secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenetic Biosciences, Inc. (XBIO)
CIK:        0001534525
Form:       8-K
Filed at:   2022-07-07T23:59:59+00:00
Accession:  0001683168-22-004819
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenetic enters manufacturing agreement with Catalent for DNase clinical supply up to $5M
--------------------------------------------------------------------------------

- Estimated project cost up to ~$5M for cGMP manufacturing of Human DNase I over ~17 months.
- Catalent to provide manufacturing services for clinical supply to support planned Phase 1 study.
- DNase platform targets NETs to enhance efficacy of immunotherapies and chemotherapies in solid tumors.
- Initial indication focus includes pancreatic carcinoma, a multi-billion-dollar market.
- CEO Jeffrey Eisenberg says this is an important step towards first-in-human studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534525/000168316822004819/0001683168-22-004819-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534525/000168316822004819/xenetic_8k-070622.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-004819

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer